Biota Of Australia Set Back In Phase I Trial Of Inavir To Prevent Flu
This article was originally published in PharmAsia News
Executive Summary
Australia's Biota Holdings experienced a major setback in a trial of its Inavir (laninamivir), already marketed for treating influenza, as a prophylactic